Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 8/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133739 | 1.00 | MAP4K4 (0.42) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL18964486 | 1.00 | MAP4K4 (0.42) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL18964485 | 1.00 | MAP4K4 (0.42) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL28377656 | 1.00 | MAP4K4 (0.42) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL22650386 | 0.88 | MAP4K4 (0.44) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL22454874 | 0.88 | MAP4K4 (0.42) | MAP4K4FPR2F2F10PRSS1 | |
| SCHEMBL18963928 | 0.84 | FPR2 (0.48) | FPR2F2F10PRSS1FPR1 | |
| SCHEMBL18963926 | 0.84 | FPR2 (0.48) | FPR2F2F10PRSS1FPR1 | |
| SCHEMBL18955180 | 0.83 | FPR2 (0.41) | FPR2FPR1 | |
| SCHEMBL18955217 | 0.83 | FPR2 (0.41) | FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | MAP4K4 2910/4885FPR2 2/4885F2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.